Какова цена за Artiva Biotherapeutics, Inc. (ARTV)

Цена за Artiva Biotherapeutics, Inc. (ARTV) Это $11.09

Какова рыночная капитализация для Artiva Biotherapeutics, Inc. (ARTV)

Рыночная капитализация для Artiva Biotherapeutics, Inc. (ARTV) Это $542.19M

Artiva Biotherapeutics, Inc. (ARTV) EPS

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy. This treatment is being developed for a broad spectrum of conditions, including autoimmune diseases like lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, systemic lupus erythematosus, and specific anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes such as granulomatosis with polyangiitis/microscopic polyangiitis, in addition to B-cell non-Hodgkin lymphoma. The company's pipeline also includes AB-201, an allogeneic anti-human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell candidate, and AB-205, another allogeneic anti-CD5 CAR-NK cell candidate. Established in 2019, Artiva Biotherapeutics is headquartered in San Diego, California.

Год	EPS	Изменить
Недостаточно данных для указанных дат.

Год

EPS

Изменить

Недостаточно данных для указанных дат.

Компания	EPS	Разница в EPS	Страна
Vertex Pharmaceuticals Incorporated VRTX.US	$17.32	-	US
Argenx SE ARGX.US	$27.74	-	NL
CSL Limited CSL.AX	$-5.29	-	AU
Moderna, Inc. MRNA.US	$-7.98	-	US
Lonza Group AG LONN.SW	-	-	CH

Компания

EPS

Разница в EPS

Страна